Skip to main content

Advertisement

SpringerLink
Log in

CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects

  • Research Article
  • Published:
Tumor Biology

Abstract

Associations between CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk are inconclusive. To derive a more precise estimation of the association, we performed a meta-analysis by searching PubMed, EMBASE, Google scholar, and WanFang databases. A total of 20 eligible articles with 39 studies were included. Of those studies, there were 21 studies for CCR5-Delta32 polymorphism, 9 studies for CCR5-59029 polymorphism, and 9 studies for CCL5-403 polymorphism. Combined analysis revealed no associations between these polymorphisms and cancer risk. However, subgroup analysis by ethnicity suggested that CCR5-59029 polymorphism was associated with the risk of cancer among Asian populations (A vs. G: odds ratio (OR) = 1.36, 95 % confidence interval (CI) 1.13–1.65, P H = 0.27; AA vs. GG: OR = 2.07, 95 % CI 1.37–3.12, P H = 0.17; GA+AA vs. GG: OR = 1.35, 95 % CI 1.03–1.77, P H = 0.92; AA vs. GA+GG: OR = 1.98, 95 % CI 1.01–3.88, P H = 0.08), but not among Caucasian populations. CCL5-403 polymorphism was associated with the risk of cancer among African populations (A vs. G: OR = 0.68, 95 % CI 0.55–0.83, P H = 0.14; AA vs. GG: OR = 0.51, 95 % CI 0.33–0.77, P H = 0.52; AG vs. GG: OR = 0.58, 95 % CI 0.42–0.80, P H = 0.14; AG+AA vs. GG: OR = 0.56, 95 % CI 0.41–0.75, P H = 0.13), but not among Caucasian populations and Asian populations. Overall, this meta-analysis indicated that CCR5-Delta32 was not associated with the risk of cancer. CCR5-59029 polymorphism contributed to cancer risk among Asian populations, and CCL5-403 polymorphism was associated with the decreased risk of cancer among African populations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Stewart TJ, Smyth MJ. Chemokine–chemokine receptors in cancer immunotherapy. Immunotherapy. 2009;1:109–27.

    Article  CAS  PubMed  Google Scholar 

  2. Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev. 2006;58:962–74.

    Article  CAS  PubMed  Google Scholar 

  3. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev. 2010;21:27–39.

    Article  CAS  PubMed  Google Scholar 

  4. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–50.

    Article  CAS  PubMed  Google Scholar 

  5. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545–53.

    Article  CAS  PubMed  Google Scholar 

  6. Weng CJ, Chien MH, Lin CW, Chung TT, Zavras AI, Tsai CM, et al. Effect of CC chemokine ligand 5 and CC chemokine receptor 5 genes polymorphisms on the risk and clinicopathological development of oral cancer. Oral Oncol. 2010;46:767–72.

    Article  CAS  PubMed  Google Scholar 

  7. Tsai HT, Yang SF, Chen DR, Chan SE. CCL5-28, CCL5-403, and CCR5 genetic polymorphisms and their synergic effect with alcohol and tobacco consumptions increase susceptibility to hepatocellular carcinoma. Med Oncol. 2012;29:2771–9.

    Article  CAS  PubMed  Google Scholar 

  8. Sáenz-López P, Carretero R, Cózar JM, Romero JM, Canton J, Vilchez JR, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer. 2008;8:382.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Liou JM, Lin JT, Huang SP, Wu CY, Wang HP, Lee YC, et al. RANTES-403 polymorphism is associated with reduced risk of gastric cancer in women. J Gastroenterol. 2008;43:115–23.

    Article  CAS  PubMed  Google Scholar 

  10. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry. 1996;35:3362–7.

    Article  CAS  PubMed  Google Scholar 

  11. Viola A, Contento RL, Molon B. T cells and their partners: the chemokine dating agency. Trends Immunol. 2006;27:421–7.

    Article  CAS  PubMed  Google Scholar 

  12. Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity. 2009;31:711–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. van Deventer HW, O'Connor Jr W, Brickey WJ, Aris RM, Ting JP, Serody JS. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res. 2005;65:3374–9.

    PubMed  Google Scholar 

  14. Molon B, Gri G, Bettella M, Gómez-Moutón C, Lanzavecchia A, Martinez AC, et al. T cell costimulation by chemokine receptors. Nat Immunol. 2005;6:465–71.

    Article  CAS  PubMed  Google Scholar 

  15. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity. 2009;30:616–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Kang SG, Piniecki RJ, Hogenesch H, Lim HW, Wiebke E, Braun SE, et al. Identification of a chemokine network that recruits FoxP3(+) regulatory T cells into chronically inflamed intestine. Gastroenterology. 2007;132:966–81.

    Article  CAS  PubMed  Google Scholar 

  17. Tan MC, Goedegebuure PS, Belt BA, Flaherty B, Sankpal N, Gillanders WE, et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol. 2009;182:1746–55.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet. 1998;352:866–70.

    Article  CAS  PubMed  Google Scholar 

  19. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.

    Article  CAS  PubMed  Google Scholar 

  20. Balistreri CR, Carruba G, Calabrò M, Campisi I, Di Carlo D, Lio D, et al. CCR5 proinflammatory allele in prostate cancer risk: a pilot study in patients and centenarians from Sicily. Ann N Y Acad Sci. 2009;1155:289–92.

    Article  CAS  PubMed  Google Scholar 

  21. Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S. Association of polymorphisms in MCP-1, CCR2, and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol. 2012;31:1418–24.

    Article  CAS  PubMed  Google Scholar 

  22. Kucukgergin C, Isman FK, Dasdemir S, Cakmakoglu B, Sanli O, Gokkusu C, et al. The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene. 2012;511:7–11.

    Article  CAS  PubMed  Google Scholar 

  23. Srivastava A, Pandey SN, Choudhuri G, Mittal B. CCR5 Delta32 polymorphism: associated with gallbladder cancer susceptibility. Scand J Immunol. 2008;67:516–22.

    Article  CAS  PubMed  Google Scholar 

  24. Zambra FM, Biolchi V, Brum IS, Chies JA. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Hum Immunol. 2013;74:1003–8.

    Article  CAS  PubMed  Google Scholar 

  25. Aoki MN, da Silva do Amaral Herrera AC, Amarante MK, do Val Carneiro JL, Fungaro MH, Watanabe MA. CCR5 and p53 codon 72 gene polymorphisms: implications in breast cancer development. Int J Mol Med. 2009;23:429–35.

    CAS  PubMed  Google Scholar 

  26. Degerli N, Yilmaz E, Bardakci F. The delta32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem. 2005;38:248–52.

    Article  CAS  PubMed  Google Scholar 

  27. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004;41:e59.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Vázquez-Lavista LG, Lima G, Gabilondo F, Llorente L. Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology. 2009;74:414–8.

    Article  PubMed  Google Scholar 

  29. Bracci PM, Skibola CF, Conde L, Halperin E, Lightfoot T, Smith A, et al. Chemokine polymorphisms and lymphoma: a pooled analysis. Leuk Lymphoma. 2010;51:497–506.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Duell EJ, Casella DP, Burk RD, Kelsey KT, Holly EA. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726–31.

    Article  CAS  PubMed  Google Scholar 

  31. Gawron AJ, Fought AJ, Lissowska J, Ye W, Zhang X, Chow WH, et al. Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population. Scand J Gastroenterol. 2011;46:333–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Khademi B, Razmkhah M, Erfani N, Gharagozloo M, Ghaderi A. SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res. 2008;14:45–50.

    Article  CAS  PubMed  Google Scholar 

  33. Singh H, Sachan R, Jain M, Mittal B. CCR5-Delta32 polymorphism and susceptibility to cervical cancer: association with early stage of cervical cancer. Oncol Res. 2008;17:87–91.

    PubMed  Google Scholar 

  34. Zheng B, Wiklund F, Gharizadeh B, Sadat M, Gambelunghe G, Hallmans G, et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res. 2006;26:3669–74.

    CAS  PubMed  Google Scholar 

  35. Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, et al. Chemokine ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African descent: a case–control study. Hered Cancer Clin Pract. 2012;10:16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, Medical College of Southeast University, Nanjing, Jiangsu, 210009, China

    Houqun Ying

  2. Key Laboratory of Developmental Genes and Human Disease, Ministry of Education, Southeast University, Nanjing, 210009, China

    Jie Wang

  3. Department of Microbiology and Immunology, Medical College of Southeast University, Nanjing, Jiangsu, 210009, China

    Xueren Gao

Authors
  1. Houqun Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xueren Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xueren Gao.

Additional information

Houqun Ying and Jie Wang have contributed equally to this work.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 17 kb)

ESM 2

(PDF 16 kb)

ESM 3

(PDF 15 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ying, H., Wang, J. & Gao, X. CCL5-403, CCR5-59029, and Delta32 polymorphisms and cancer risk: a meta-analysis based on 20,625 subjects. Tumor Biol. 35, 5895–5904 (2014). https://doi.org/10.1007/s13277-014-1780-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1780-9

Keywords

Search

Navigation